Cancer: Capecitabine (Xeloda)

Mechanism of action for Capecitabine (Xeloda).

EFP Website: www.efp-online.org.

European Fellowship for Pharmacists

Category:

Science & Technology

Tags:

• cancer
• capecitabine
• capécitabine
• xeloda
• fluorouracile
• FU
• 5-FU
• mechanism
• of
• action
• oncology
• drugs
• oncologie
• cancerologie
• health
• hospital
• treatment
• science
• doctor
• therapy
• sein
• breast
• instructional video
• educational

[Allibaby78]

Capecitabine is FDA-approved (USA) for:

Adjuvant in colorectal cancer Stage III Dukes' C - used as first-line monotherapy.

Metastatic colorectal cancer - used as first-line monotherapy, if appropriate.

Metastatic breast cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. Also as monotherapy, for failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons

[Allibaby78]

Capecitabine is a chemotherapy drug used to treat some cancers including breast cancer, bowel cancer, stomach cancer and pancreatic cancer. It is one of a group of chemotherapy drugs known as the anti-metabolites. These stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply.

[Allibaby78]

Capecitabine (INN) (Xeloda, Roche) is an oral chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue . Activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.